Market Cap 4.93B
Revenue (ttm) 1.36B
Net Income (ttm) 120.36M
EPS (ttm) N/A
PE Ratio 24.15
Forward PE 26.51
Profit Margin 8.87%
Debt to Equity Ratio 0.49
Volume 546,400
Avg Vol 587,178
Day's Range N/A - N/A
Shares Out 59.22M
Stochastic %K 61%
Beta 0.58
Analysts Strong Sell
Price Target $103.20

Company Profile

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as verte...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 801 253 1600
Fax: 801 253 1652
Address:
1600 West Merit Parkway, South Jordan, United States
prismmarketview
prismmarketview Oct. 16 at 1:28 PM
(NASDAQ: $MMSI) #MeritMedical announced a $22M deal to acquire the C2 CryoBalloon technology from Pentax of America, expanding its endoscopy portfolio. The minimally invasive GI device targets Barrett’s esophagus and GERD. https://prismmarketview.com/merit-medical-expands-gi-portfolio-with-22m-acquisition-of-c2-cryoballoon-technology/
0 · Reply
ZacksResearch
ZacksResearch Oct. 16 at 1:20 PM
$MMSI set to expand with C2 CryoBalloon acquisition — long-term growth play in GI market? 💡 📉 Stock down 16.8% YTD vs. industry’s 1.9% decline 💰 $22M deal opens doors to multibillion-dollar gastroenterology segment 📈 Revenue contributions expected to ramp up in 2026, despite near-term earnings pressure Discover the strategic move here 👉 https://www.zacks.com/stock/news/2769967/merit-medical-expands-gi-portfolio-with-22m-c2-cryoballoon-acquisition?cid=sm-stocktwits-2-2769967-body-16313&ADID=SYND_STOCKTWITS_TWEET_2_2769967_BODY_16313
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 16 at 12:45 PM
$MMSI (+1.9% pre) C2 CryoBalloon product line sold to Merit Medical; PENTAX Medical refocuses on flexible reusable endoscopy https://ooc.bz/l/80764
0 · Reply
ZacksResearch
ZacksResearch Oct. 16 at 12:21 PM
$MMSI just made a bold move into GI growth territory 👀 The $22M acquisition of C2 CryoBalloon from Pentax expands its gastroenterology lineup — a short-term hit, but a long-term play for stronger positioning in the GI market. See the full growth rationale here 👉 https://www.zacks.com/stock/news/2769967/merit-medical-expands-gi-portfolio-with-22m-c2-cryoballoon-acquisition?cid=sm-stocktwits-2-2769967-teaser-16312&ADID=SYND_STOCKTWITS_TWEET_2_2769967_TEASER_16312
0 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 11:20 AM
Canaccord Genuity has updated their rating for Merit Medical Systems ( $MMSI ) to Buy with a price target of 104.
0 · Reply
DonCorleone77
DonCorleone77 Oct. 15 at 8:26 PM
$MMSI Merit Medical to acquire C2 CryoBalloon device for $22M, sees dilution
0 · Reply
BearScout
BearScout Oct. 5 at 12:12 PM
$MMSI Healthcare technology growth. Testing resistance level. Volume confirmation needed. Sector momentum building.
0 · Reply
JarvisFlow
JarvisFlow Sep. 23 at 3:19 PM
Barrington Research updates rating for Merit Medical Systems ( $MMSI ) to Outperform, target set at 103.
0 · Reply
ZacksResearch
ZacksResearch Sep. 15 at 6:24 PM
$MMSI secures a CE Mark for knee OA treatment — shares plunged 5.2%, but not due to the news. 🤔 🔹 Expanded market opportunity with Embosphere for genicular artery embolisation 🔹 Proven tech with 25+ years of clinical use 🔹 Shares still down 11.6% YTD despite industry decline of 1.8% What’s next for MMSI? Full breakdown here 👉 https://www.zacks.com/stock/news/2751711/mmsi-stock-falls-despite-ce-mark-win-for-embosphere-in-knee-oa-care?cid=sm-stocktwits-2-2751711-body-12511&ADID=SYND_STOCKTWITS_TWEET_2_2751711_BODY_12511
0 · Reply
ZacksResearch
ZacksResearch Sep. 15 at 5:24 PM
$MMSI drops even after a CE Mark win — what gives? ⚠️ The company just secured approval to expand Embosphere into knee osteoarthritis care, offering a minimally invasive treatment option. See the full bull/bear setup here 👉 https://www.zacks.com/stock/news/2751711/mmsi-stock-falls-despite-ce-mark-win-for-embosphere-in-knee-oa-care?cid=sm-stocktwits-2-2751711-teaser-12507&ADID=SYND_STOCKTWITS_TWEET_2_2751711_TEASER_12507
0 · Reply
Latest News on MMSI
The Market Is Vulnerable. 6 ‘Defensive' Stocks to Buy Now.

Jun 9, 2025, 12:46 PM EDT - 4 months ago

The Market Is Vulnerable. 6 ‘Defensive' Stocks to Buy Now.

CRM EXC MSI


Merit Medical Acquires Biolife Delaware, L.L.C.

May 20, 2025, 7:30 AM EDT - 5 months ago

Merit Medical Acquires Biolife Delaware, L.L.C.


Merit Medical Launches the Ventrax™ Delivery System

Apr 9, 2025, 9:25 AM EDT - 7 months ago

Merit Medical Launches the Ventrax™ Delivery System


Merit Medical: A Success Story That Keeps Getting Better

Mar 16, 2025, 12:34 PM EDT - 7 months ago

Merit Medical: A Success Story That Keeps Getting Better


First Patient Enrolled in Merit Medical's PREEMIE Study

Mar 10, 2025, 9:25 AM EDT - 8 months ago

First Patient Enrolled in Merit Medical's PREEMIE Study


Merit Medical Announces Resignation of President, Joseph Wright

Dec 16, 2024, 4:00 PM EST - 11 months ago

Merit Medical Announces Resignation of President, Joseph Wright


Merit Medical Launches basixSKY™ Inflation Device

May 21, 2024, 9:25 AM EDT - 1 year ago

Merit Medical Launches basixSKY™ Inflation Device


Merit Medical Executive Leadership Team Update

May 15, 2024, 4:05 PM EDT - 1 year ago

Merit Medical Executive Leadership Team Update


prismmarketview
prismmarketview Oct. 16 at 1:28 PM
(NASDAQ: $MMSI) #MeritMedical announced a $22M deal to acquire the C2 CryoBalloon technology from Pentax of America, expanding its endoscopy portfolio. The minimally invasive GI device targets Barrett’s esophagus and GERD. https://prismmarketview.com/merit-medical-expands-gi-portfolio-with-22m-acquisition-of-c2-cryoballoon-technology/
0 · Reply
ZacksResearch
ZacksResearch Oct. 16 at 1:20 PM
$MMSI set to expand with C2 CryoBalloon acquisition — long-term growth play in GI market? 💡 📉 Stock down 16.8% YTD vs. industry’s 1.9% decline 💰 $22M deal opens doors to multibillion-dollar gastroenterology segment 📈 Revenue contributions expected to ramp up in 2026, despite near-term earnings pressure Discover the strategic move here 👉 https://www.zacks.com/stock/news/2769967/merit-medical-expands-gi-portfolio-with-22m-c2-cryoballoon-acquisition?cid=sm-stocktwits-2-2769967-body-16313&ADID=SYND_STOCKTWITS_TWEET_2_2769967_BODY_16313
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 16 at 12:45 PM
$MMSI (+1.9% pre) C2 CryoBalloon product line sold to Merit Medical; PENTAX Medical refocuses on flexible reusable endoscopy https://ooc.bz/l/80764
0 · Reply
ZacksResearch
ZacksResearch Oct. 16 at 12:21 PM
$MMSI just made a bold move into GI growth territory 👀 The $22M acquisition of C2 CryoBalloon from Pentax expands its gastroenterology lineup — a short-term hit, but a long-term play for stronger positioning in the GI market. See the full growth rationale here 👉 https://www.zacks.com/stock/news/2769967/merit-medical-expands-gi-portfolio-with-22m-c2-cryoballoon-acquisition?cid=sm-stocktwits-2-2769967-teaser-16312&ADID=SYND_STOCKTWITS_TWEET_2_2769967_TEASER_16312
0 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 11:20 AM
Canaccord Genuity has updated their rating for Merit Medical Systems ( $MMSI ) to Buy with a price target of 104.
0 · Reply
DonCorleone77
DonCorleone77 Oct. 15 at 8:26 PM
$MMSI Merit Medical to acquire C2 CryoBalloon device for $22M, sees dilution
0 · Reply
BearScout
BearScout Oct. 5 at 12:12 PM
$MMSI Healthcare technology growth. Testing resistance level. Volume confirmation needed. Sector momentum building.
0 · Reply
JarvisFlow
JarvisFlow Sep. 23 at 3:19 PM
Barrington Research updates rating for Merit Medical Systems ( $MMSI ) to Outperform, target set at 103.
0 · Reply
ZacksResearch
ZacksResearch Sep. 15 at 6:24 PM
$MMSI secures a CE Mark for knee OA treatment — shares plunged 5.2%, but not due to the news. 🤔 🔹 Expanded market opportunity with Embosphere for genicular artery embolisation 🔹 Proven tech with 25+ years of clinical use 🔹 Shares still down 11.6% YTD despite industry decline of 1.8% What’s next for MMSI? Full breakdown here 👉 https://www.zacks.com/stock/news/2751711/mmsi-stock-falls-despite-ce-mark-win-for-embosphere-in-knee-oa-care?cid=sm-stocktwits-2-2751711-body-12511&ADID=SYND_STOCKTWITS_TWEET_2_2751711_BODY_12511
0 · Reply
ZacksResearch
ZacksResearch Sep. 15 at 5:24 PM
$MMSI drops even after a CE Mark win — what gives? ⚠️ The company just secured approval to expand Embosphere into knee osteoarthritis care, offering a minimally invasive treatment option. See the full bull/bear setup here 👉 https://www.zacks.com/stock/news/2751711/mmsi-stock-falls-despite-ce-mark-win-for-embosphere-in-knee-oa-care?cid=sm-stocktwits-2-2751711-teaser-12507&ADID=SYND_STOCKTWITS_TWEET_2_2751711_TEASER_12507
0 · Reply
Danyzinho29
Danyzinho29 Aug. 28 at 8:40 AM
$MMSI cup with handle formation here?
0 · Reply
ZacksResearch
ZacksResearch Jul. 31 at 5:54 PM
$MMSI beats EPS estimates by 17.4% — is the stock set for a rally? 🚀 Merit Medical's adjusted EPS rose to $1.01 with revenues hitting $382.5M, up 13.2% year over year on a reported basis. U.S. sales surged 16.7%, outpacing projections and bolstering investor confidence. Complete risk/reward breakdown here 👉 https://www.zacks.com/stock/news/2644951/merit-medical-q2-earnings-beat-estimates-gross-margin-expands?cid=sm-stocktwits-2-2644951-body-5236&ADID=SYND_STOCKTWITS_TWEET_2_2644951_BODY_5236
0 · Reply
ZacksResearch
ZacksResearch Jul. 31 at 4:48 PM
$MMSI just delivered a clean Q2 beat — here’s what drove it 💥 Gross margin expanded and strong U.S. + Cardiovascular sales pushed revenue higher, beating earnings estimates for Q2 2025. Full breakdown of the bullish setup here 👉 https://www.zacks.com/stock/news/2644951/merit-medical-q2-earnings-beat-estimates-gross-margin-expands?cid=sm-stocktwits-2-2644951-teaser-5175&ADID=SYND_STOCKTWITS_TWEET_2_2644951_TEASER_5175
0 · Reply
JarvisFlow
JarvisFlow Jul. 31 at 2:36 PM
Raymond James has updated their rating for Merit Medical Systems ( $MMSI ) to Outperform with a price target of 102.
0 · Reply
JarvisFlow
JarvisFlow Jul. 31 at 2:01 PM
Piper Sandler updates rating for Merit Medical Systems ( $MMSI ) to Overweight, target set at 110 → 105.
0 · Reply
JarvisFlow
JarvisFlow Jul. 31 at 12:30 PM
Barrington Research has adjusted their stance on Merit Medical Systems ( $MMSI ), setting the rating to Outperform with a target price of 103.
0 · Reply
Bobky2030
Bobky2030 Jul. 31 at 10:21 AM
$MMSI big earnings beat and guided up. Back above 90.00
0 · Reply
Bobky2030
Bobky2030 Jul. 31 at 10:13 AM
$MMSI Reports Q2 (Jun) earnings of $1.01 per share, excluding non-recurring items, $0.16 better than the FactSet Consensus of $0.85; revenues rose 13.2% year/year to $382.46 mln vs the $374.15 mln FactSet Consensus. Co issues upside guidance for FY25, sees EPS of $3.52-3.72, excluding non-recurring items, vs. $3.35 FactSet Consensus; sees FY25 revs of $1.495-1.507 bln vs. $1.49 bln FactSet Consensus
0 · Reply
d_risk
d_risk Jul. 31 at 10:00 AM
$MMSI - Merit Medical Systems Inc. Common Stock - 10Q - Updated Risk Factors MMSI’s 10-Q highlights rising risks from trade tensions disrupting costs and supply chains, financial market volatility impacting capital access, and leadership transition challenges amid competitive labor markets and inflation. #MedicalDevices #LaborMarketChallenges #FinancialVolatility #SupplyChainRisk #TradeTensions 🟢 Added 🟠 Removed https://d-risk.ai/MMSI/10-Q/2025-07-30
0 · Reply
JasonCO
JasonCO Jul. 30 at 8:39 PM
$MMSI nice report . dumped it
0 · Reply
CatCapital_ai
CatCapital_ai Jul. 30 at 8:22 PM
$MMSI Earnings - Q2/2025 Revenue: $382.5M ✅ vs. $372.47M est. EPS: $1.01 ✅ vs. $0.85 est. Merit Medical exceeds expectations with 13.2% revenue growth and raises full-year guidance. Strong H1 results boost confidence in continued stable growth and improved profitability outlook for 2025.
0 · Reply
Bobky2030
Bobky2030 Jul. 30 at 4:24 PM
$MMSI MMSI. Earnings tonight. Low float. Big shorts. Be a great MEME stock
0 · Reply